UMIN ID: UMIN000000955
Registered date:24/12/2007
Cancer therapy with vaccination using HLA-A24-restricted peptide from URLC10:a phase I study in patient with unresectable esophageal cancer
Basic Information
| Recruitment status | Complete: follow-up complete |
|---|---|
| Health condition(s) or Problem(s) studied | unresectable esophageal cancer |
| Date of first enrollment | 2005/10/01 |
| Target sample size | 6 |
| Countries of recruitment | Japan |
| Study type | Interventional |
| Intervention(s) | Vaccination using epitope peptide from URLC10 |
Outcome(s)
| Primary Outcome | safety |
|---|---|
| Secondary Outcome |
Key inclusion & exclusion criteria
| Age minimum | 20years-old |
|---|---|
| Age maximum | 75years-old |
| Gender | Male and Female |
| Include criteria | |
| Exclude criteria | pregnancy uncontroled infection uncontroled cerebral metastasis etc |
Related Information
| Primary Sponsor | Institute of Medical Science The University of Tokyo |
|---|---|
| Secondary Sponsor | |
| Source(s) of Monetary Support | Government |
| Secondary ID(s) |
Contact
| public contact | |
| Name | |
| Address | Japan |
| Telephone | |
| kanamoto@ims.u-tokyo.ac.jp | |
| Affiliation | Institute of Medical Science surgery and bioengineering |
| scientific contact | |
| Name | Kanamoto Akira |
| Address | 4-6-1,shirokanedai minato-ku tokyo,Japan Japan |
| Telephone | |
| Affiliation | Institute of Medical Science The University of Tokyo surgery and bioengineering |